Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health has completed the acquisition of Kindred Biosciences for $444 million, enhancing its position in the dermatology market. This acquisition is expected to bring three potential blockbusters by 2025 and add $100 million to Elanco's innovation revenue, totaling $600-$700 million. The partnership is poised to boost Elanco's annual revenue growth by 1% starting in 2024 and improve gross margins. This strategic move strengthens Elanco's commitment to addressing unmet medical needs for pets.

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021. CEO Jeff Simmons will join a virtual fireside chat at 3:30 p.m. ET. Investors can access a live audio webcast on Elanco's investor website, with a replay available for 90 days.

Elanco is a leader in animal health, focusing on innovative solutions for the well-being of farm animals and pets. With nearly 70 years of experience, they aim to enhance animal health and contribute positively to communities worldwide.

Elanco Animal Health (NYSE: ELAN) reported robust Q2 2021 results, highlighting revenue of $1,279 million, exceeding guidance by $39 million, and a reported net loss of $210 million. This marks a 118% increase in revenue year-over-year, largely due to the acquisition of Bayer Animal Health. Adjusted EPS rose to $0.28, outperforming guidance, while adjusted EBITDA reached $291 million. The company raised its full-year revenue guidance for the third time in 2021, reflecting confidence in continued growth. Concerns include a subpoena from the SEC related to inventory practices and operational impacts from pandemic challenges.

TriRx Pharmaceutical Services has completed the acquisition of Elanco Animal Health's manufacturing site in Shawnee, Kansas, effective August 1, 2021. The transaction aims to enhance TriRx's position in the pharmaceutical contract development and manufacturing market. Approximately 300 employees will transition to TriRx, which plans to expand operations and invest in the facility. Furthermore, a long-term supply agreement ensures continued production of Elanco's products. This acquisition is part of TriRx's strategy to meet the growing needs in the Animal and Human Health markets.

Elanco Animal Health (NYSE: ELAN) will announce its Q2 2021 financial results on August 9, 2021, at 8:00 AM ET. The announcement will be followed by a conference call to discuss the company's performance with investors and the media. A live webcast will be available on Elanco's website, and a replay will be accessible shortly after the call. With nearly 70 years in the animal health sector, Elanco remains committed to innovating products that enhance the health of farm animals and pets, while also pursuing sustainability through its Elanco Healthy Purpose™ initiatives.